+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Drugs for Vulvovaginal Candidiasis Market Size: By Formulation Type, By End User, and By Region; Trend Analysis, Competitive Market Share & Forecast, 2016-26

  • PDF Icon


  • 180 Pages
  • February 2020
  • Region: Global
  • Blueweave Consulting & Research Pvt Ltd
  • ID: 5012804
The Global Drugs for Vulvovaginal Candidiasis (VVC) Market is projected to reach the valuation of USD 1,006 million by the year 2026 by growing at a CAGR of 3.76% during the forecast period 2019- 2026. The key factors that are propelling the market are the increase in the number of patients affected by candidiasis infection and high acceptance due to innovative vulvovaginal candidiasis drugs during the forecast horizon.

The drug is formulated in various forms, including pessary, topical, and oral. The surging number of patients affected by the candidiasis infection, coupled with the growing acceptance of innovative drugs, are some of the significant factors expected to stimulate demand from the vulvovaginal candidiasis market. The increasing consumer awareness of candidiasis and increasing number of treatment options are major drivers of candidiasis market growth. In addition, approaches such as mergers and business behemoths acquisitions and partnerships are possible to provide a tailwind to the worldwide market for vulvovaginal candidiasis (VVC) drugs.

Moreover, factor driving the market growth is expected to be the increasing awareness of hygiene among people in developing countries. Globally, market players are involved in innovating new product development, which is likely to support market growth over the forecast period.

The Topical Type segment in Formulation Type is expected to grow at the highest rate during Forecast horizon

On the premises of Formulation Type, the Topical segment will propel the market for Vulvovaginal Candidiasis Drugs owing to the growing demand from small and medium-sized enterprises, and various industry verticals would provide enough room for market growth over the forecast period. Topical is used to treat diseases of vaginal yeast, which reduces vaginal pain, itching, and discharge with this condition. This drug is an antifungal azole, which works by averting the growth of the infection-causing yeast (Fungus).

Rising Incidences of Candidiasis Driving Adoption of VVC Drugs Market

The main contributing factor projected to fuel the growth of the demand for VVC drugs over the forecast period is the increase in the incidence of VVC infections. The increase in the research and development activities by the pharmaceutical manufacturers for the production of novel antifungals are propelling the market growth of the global drugs for the Vulvovaginal Candidiasis (VVC). The class of drugs called Azoles is widely used to treat systematic fungal infection, which is also known as imidazoles. Triazoles such as fluconazole, voriconazole, and itraconazole have a strong wide-spectrum action and offer higher levels of safety compared to other therapeutic agents. The triazoles have fewer adverse effects, and extreme reactions between products and medicines and have enhanced pharmacokinetic properties. Completely these advantages lead to the current azoles supremacy among other drug classes.

Increasing R&D expenditure and the expansion of the product pipeline by pharmaceutical manufacturers

In recent years, the market for the treatment of fungal diseases has sprouted a number of highly effective and safe antifungal agents. Some of the most effective therapies on the market are terbinafine, itraconazole, fluconazole. The increasing Research & Department expenditure and expanding the pharmaceutical manufacturers ' advanced product pipeline for anti-infective development is one of the significant factors contributing to the growth of the antifungal drug sector. Players are focusing on developing effective therapeutic agents in immunocompromised patients to treat systemic fungal infections. Different frameworks for public-private cooperation to develop new technologies are expected to give the sector tremendous growth opportunities.

North America is anticipated to dominate the lion’s share of global Drugs for Vulvovaginal Candidiasis (VVC) market during the anticipated period

By geography, the global Drugs for Vulvovaginal Candidiasis (VVC) Market segregated into North America, Europe, Asia Pacific, Middle East & Africa, and Latin America. North America is expected to dominate the market, due to the growing incidence of vulvovaginal candidiasis (VVC) among the population in the region would drive the growth of the sector. The prevalence of sedentary lifestyles has a major impact on women's health. Changing lifestyles, particularly among the working population, had an impact on women's health, which has contributed to these illnesses. In addition, changes in eating habits have influenced health, especially among the working women population.

Drugs for Vulvovaginal Candidiasis (VVC) Market: Competitive Landscape

The major market players in the Global Drugs for Vulvovaginal Candidiasis (VVC) are Bayer, Perrigo, J & J, Pfizer, Bristol-Myers Squibb, Effik, Teva, Sanofi, Cisen Pharmaceutical, Kingyork Group, Janssen, Actavis, Tianjin Kingyork Group, Tianjin Pacific Pharmaceutical, Lunan Pharmaceutical, Viamet Pharmaceuticals, and other Prominent Players are expanding their presence in the market by implementing various innovations and technologies.

This product will be delivered within 2 business days.

Table of Contents

1. Research Framework
1.1. Research Objective
1.2. Product Overview
1.3. Market Segmentation
2. Research Methodology
2.1. Qualitative Research
2.1.1. Primary & Secondary Sources
2.2. Quantitative Research
2.2.1. Primary & Secondary Sources
2.3. Breakdown of Primary Research Respondents, By Region
2.3.1. Secondary Research
2.3.2. Primary Research
2.4. Breakdown of Primary Research Respondents
2.5. Market Size Estimation
2.6. Assumption for the Study
2.7. Market Breakdown & Data Triangulation
3. Global Drugs for Vulvovaginal Candidiasis (VVC) Market Industry Insights
3.1. DROC Analysis
3.1.1. Growth Drivers
3.1.2. Restraints
3.1.3. Opportunities
3.1.4. Challenges
3.2. Technological Landscape
3.3. Regulatory Framework
3.4. Company market share analysis, 2019
3.5. Porter’s Five forces analysis
3.5.1. Bargaining Power of Suppliers
3.5.2. Bargaining Power of Buyers
3.5.3. Threat of New Entrants
3.5.4. Threat of Substitutes
3.5.5. Intensity of Rivalry
4. Global Drugs for Vulvovaginal Candidiasis (VVC) Market Overview
4.1. Market Size & Forecast 2016-2026
4.1.1. By Value (USD)
4.2. Market Share & Forecast
4.2.1. By Formulation Type Topical (Cream, Lotion, Gel, Ointment, Aerosol, Foam, Powder, Solution etc.) Pessary (Suppositories, Kit) Oral (Tablet, Capsule, Powder for Suspension etc.)
4.2.2. By Drug Type Miconazole Clotrimazole Fluconazole Econazole Others (Itraconazole, Nystatin, Tioconazole, amphotericin B Etc.)
4.2.3. By End User Hospital Clinic Pharmacy
4.2.4. By Region North America Europe Asia Pacific Latin America Middle East & Africa
5. North America Drugs for Vulvovaginal Candidiasis (VVC) Market
5.1. Market estimates & forecast
5.1.1. By Formulation Type
5.1.2. By Drug Type
5.1.3. By End user
5.1.4. By Country U.S Canada
6. Europe Drugs for Vulvovaginal Candidiasis (VVC) Market
6.1. Market estimates & forecast
6.1.1. By Formulation Type
6.1.2. By Drug Type
6.1.3. By End user
6.1.4. By Country Germany U.K France Italy Rest of Europe
7. Asia Pacific Drugs for Vulvovaginal Candidiasis (VVC) Market
7.1. Market estimates & forecast
7.1.1. By Formulation Type
7.1.2. By Drug Type
7.1.3. By End user
7.1.4. By Country China India Japan Rest of APAC
8. Latin America Drugs for Vulvovaginal Candidiasis (VVC) Market
8.1. Market estimates & forecast
8.1.1. By Formulation Type
8.1.2. By Drug Type
8.1.3. By End user
8.1.4. By Country Brazil Argentina Rest of Latin America
9. Middle East & Africa Drugs for Vulvovaginal Candidiasis (VVC) Market
9.1. Market estimates & forecast
9.1.1. By Formulation Type
9.1.2. By Drug Type
9.1.3. By End user
9.1.4. By Country Saudi Arabia UAE South Africa Rest of MEA
10. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Strategic Outlook) *
10.1. Bayer
10.2. Perrigo
10.3. J & J
10.4. Pfizer
10.5. Bristol-Myers Squibb
10.6. Effik
10.7. Teva
10.8. Sanofi
10.9. Cisen Pharmaceutical
10.10. Kingyork Group
10.11. Janssen
10.12. Actavis
10.13. Tianjin Kingyork Group
10.14. Tianjin Pacific Pharmaceutical
10.15. Lunan Pharmaceutical
10.16. Viamet Pharmaceuticals
10.17. Other Prominent Players
* Financial information of non-listed Companies will be provided as per availability
**The segmentation and the companies are subjected to modifications based on in-depth secondary for the final deliverable

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Bayer
  • Perrigo
  • J & J
  • Pfizer
  • Bristol-Myers Squibb
  • Effik
  • Teva
  • Sanofi
  • Cisen Pharmaceutical
  • Kingyork Group
  • Janssen
  • Actavis
  • Tianjin Kingyork Group
  • Tianjin Pacific Pharmaceutical
  • Lunan Pharmaceutical
  • Viamet Pharmaceuticals